European Inspectors Spot GMP Deficiencies In India During ‘Virtual Tours’
It Almost Felt Like We Were There, Says EDQM Inspector
A senior inspector at the European Directorate for the Quality of Medicines & HealthCare explained how some “out-of-the-box thinking” was leading to a new approach for inspecting companies.
You may also be interested in...
Dr Reddy’s global head of quality outlines how the company leveraged digitization to keep plants running at full throttle amid the pandemic and went on to operationalize a site for remdesivir designed as a "lights out" facility. Certain facilities at the Indian firm have also undergone remote inspections by major regulatory agencies.
The European Medicines Agency has recommended pan-EU marketing approval for four medicines but turned down Ipsen’s treatment for an ultra-rare bone disorder. It has also OK’d new uses of seven already-approved drugs and is reviewing efficacy concerns regarding Novartis’ sickle cell medicine.
A survey undertaken last year on the implementation of the EU Clinical Trials Regulation drew some positive feedback from study sponsors but also threw light on well-known concerns with the legislation. Some of the highlighted issues are being addressed on a priority basis.